ESMO 2019 | Efficacy of lorlatinib in NSCLC post-second generation ALK TKI

Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the intracranial and extracranial efficacy of lorlatinib in the post-second generation ALK tyrosine kinase inhibitor setting for non-small cell lung cancer (NCT01970865). He highlights the importance of splitting the overall response rate by intracranial and extracranial efficacy.